{"id":3321,"date":"2021-09-10T13:11:19","date_gmt":"2021-09-10T11:11:19","guid":{"rendered":"https:\/\/mga.local\/projekt\/hepacor-study\/"},"modified":"2021-09-19T19:00:52","modified_gmt":"2021-09-19T17:00:52","slug":"hepacor-study","status":"publish","type":"project","link":"https:\/\/medixbank.com\/en\/projekt\/hepacor-study\/","title":{"rendered":"Hepacor study"},"content":{"rendered":"\n
Introduction<\/h5>\n\n\n\n

Recently, there has been significant progress made in the antiviral treatment of hepatitis C, with a success rate of almost 100%. Based on previous epidemiological surveys, we assume that despite the low incidence of hepatitis C in Slovakia, a significant proportion of infected patients remain undetected and therefore untreated. Higher incidence of infection can be expected especially in people with increased aminotransferase activity (so-called liver tests) or the presence of some of the risk factors for the transmission of infection.<\/p>\n\n\n\n

<\/p>\n\n\n\n

\u201eThe aim of the study is to evaluate the correlation between the incidence of hepatitis C virus infection and at-risk populations. The results will be helpful in the targeted preparation of future hepatitis C screening strategies in order to make treatment accessible to all the infected individuals, including those who have yet been unware of their infection.\u201c<\/blockquote><\/div>
<\/div>

Doc. MUDr. Pavol Kristian PhD<\/p>

Professional supervisor of the project<\/p><\/div><\/div><\/div>\n\n\n\n

<\/p>\n\n\n\n

\n
Brief description of the study:<\/h5>\n\n\n\n

The Hepacor study<\/strong> is conducted to describe the relationship between risk groups and the incidence of hepatitis C virus (HCV) infection in the Slovak Republic<\/p>\n\n\n\n

The study involves:<\/p>\n\n\n\n

  • MEDIREX GROUP ACADEMY n.o<\/strong>. as the “party implementing the research project “;<\/li>
  • 80 centers <\/strong>\u2013 health care providers in the field of general medicine and internal medicine in Slovakia as “investigators”;<\/li>
  • 1500 patients from the Ko\u0161ice and Bratislava self-governing regions who met the admission and exclusion criteria of the study were gradually included in the study.\n\n<\/strong><\/li>
  • The enrolled patient provides his\/her medical history data with a focus on risk factors for HCV infection, as well as blood samples are collected for the detection of antibodies to the hepatitis C virus (HCV).<\/li><\/ul>\n\n\n\n

    Zobrazi\u0165 cel\u00fd text<\/p><\/div>

    \n

    The determination of anti-HCV antibodies by chemiluminescent microparticle immunoassay (CMIA)<\/strong> is used in the project for the primary detection of hepatitis C virus carriers. Positive findings are subsequently confirmed by evidence using the HCV RNA by PCR (Polymerase chain reaction).<\/p>\n\n\n\n

    <\/p>\n\n\n\n

    Anamnestic data, as well as test results, are recorded in the eCRF system and subsequently evaluated.<\/p>\n\n\n\n

    No drug is validated in the study<\/strong>. This study is for observational purposes only and the schedule of outpatient visits, and all treatment regimens are determined by the attending physician in accordance with standard clinical practice.<\/p>\n<\/div>

    Skry\u0165 text<\/p><\/div><\/div>\n<\/div>\n\n\n\n

    \n
    Goals<\/h5>\n\n\n\n

    The aim of the study is to evaluate the correlation between hepatitis C virus carriers and risk groups.<\/p>\n<\/div>\n\n\n\n

    \n
    Activities<\/h5>\n\n\n\n
    • Patient recruitment<\/strong>
      Date: 1.5.2015 to 31.7.2016<\/em><\/li>
    • Completion of data collection<\/strong>
      Date: 31.8.2016<\/em><\/li>
    • Statistical processing and evaluation of the collected data<\/strong>
      Date: 9\/1\/2016 to 9\/30\/2016<\/em><\/li>
    • Publication of results<\/strong>
      Date: 1.9.2016 – 31.12.2016<\/em><\/li><\/ul>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

      The Hepacor CZ study is conducted in order to describe the relationship between risk groups and the carrier of hepatitis C virus (HCV) in the Czech Republic.<\/p>\n","protected":false},"author":1,"featured_media":0,"template":"","meta":[],"project_category":[24],"acf":[],"_links":{"self":[{"href":"https:\/\/medixbank.com\/en\/wp-json\/wp\/v2\/project\/3321"}],"collection":[{"href":"https:\/\/medixbank.com\/en\/wp-json\/wp\/v2\/project"}],"about":[{"href":"https:\/\/medixbank.com\/en\/wp-json\/wp\/v2\/types\/project"}],"author":[{"embeddable":true,"href":"https:\/\/medixbank.com\/en\/wp-json\/wp\/v2\/users\/1"}],"wp:attachment":[{"href":"https:\/\/medixbank.com\/en\/wp-json\/wp\/v2\/media?parent=3321"}],"wp:term":[{"taxonomy":"project_category","embeddable":true,"href":"https:\/\/medixbank.com\/en\/wp-json\/wp\/v2\/project_category?post=3321"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}